Symbols

SRPT

Sarepta·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Gap Up

Significant Net Income Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SRPT

Sarepta Therapeutics, Inc.

A commercial-stage biopharmaceutical company focused on unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities

Industry

Pharmaceutical

Established Date

07/22/1980

Listing Date

06/04/1997

Exchange

NASDAQ Stock Exchange

Full-time Employees

835

Fiscal Year Ends

12-31

Website

www.sarepta.com

Security Type

Common stock

Office address

215 First Street, Suite 415, Cambridge, MA 02142

Business

Introduction

Sarepta Therapeutics, Inc., was incorporated in Oregon on July 22, 1980. The Company is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapies, gene therapies and other genetic therapies for the treatment of rare diseases. It has developed a variety of approved Duchenne muscular dystrophy treatments and is advancing drug candidates for other neuromuscular and skeletal diseases.

Company Financials

EPS

SRPT has released its 2025 Q4 earnings. EPS was reported at -3.58, versus the expected -1.21, missing expectations. The chart below visualizes how SRPT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SRPT has released its 2025 Q4 earnings report, with revenue of 442.93M, reflecting a YoY change of -32.73%, and net profit of -412.23M, showing a YoY change of -359.18%. The Sankey diagram below clearly presents SRPT's revenue sources and cost distribution.